Clinical Trial Update: CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases [Phase 3]

View source ↗

Summary

CER-001 therapy in Phase 3 for Familial hypoalphalipoproteinemia was terminated. Results from the terminated trial have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypoalphalipoproteinemia

Drugs mentioned

• CER-001

Snippet

Sponsor: Cerenis Therapeutics, SA | Conditions: Familial Hypoalphalipoproteinemia | Phase 3 | Status: TERMINATED | Results posted: 2025-07-22